651 results about "Treatment regimen" patented technology

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

Provided herein is a consensus molecular subtype (CMS) classifier for colorectal cancer patients. Also provided are methods of using the classifier to identify a clinically beneficial therapeutic regime for each patient as well as methods of treating a patient accordingly Custom Nanostring code sets, which work on formalin-fixed, paraffin-embedded samples, are provide for use in determining the CMS for a colorectal cancer patient.

A system for dispensing hair care formulations including a communication device that includes processing circuitry capable of taking a photo of a user's hair, uploading the photo into an application on a communication device, applying an algorithm to the photo to detect one or more hair features, sensing one or more environmental conditions with one or more sensors, and recommending a hair care treatment regimen of one or more hair care formulas based on the one or more hair features, and the one or more environmental conditions. The system also includes one or more cartridges containing one or more hair care formulas, and a dispensing device configured to dispense one or more hair care formulas from the one or more cartridges based on the hair care treatment regimen.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The invention discloses a nerve postoperative pain monitoring and feedback method and system, and relates to the technical field of medical information, and the method comprises the following components: a data acquisition step, a digital twin model construction step, a pain simulation step, a visualization and interaction step and a feedback and scheme making step. By constructing the digital twinborn model of the postoperative body of the patient, the postoperative physiological structure, the nerve function state and the pain-related physiological mechanism of the patient can be accurately simulated, and based on the model, a doctor can simulate different treatment schemes and pain responses under external stimulation, so that a more personalized pain management scheme is formulated, and the pain management efficiency is improved. According to the personalized management mode, the accuracy of pain management is remarkably improved, postoperative pain of the patient can be relieved more effectively, and the treatment experience and satisfaction degree of the patient are improved.

The invention discloses a brain tumor disease treatment effect evaluation method, and belongs to the technical field of radiotherapy plan evaluation, and the method specifically comprises the steps: obtaining the brain multi-modal image data of a patient, and extracting a three-dimensional tumor region and a corresponding perfusion parameter; constructing a biological target region hierarchical structure containing a tumor overall region and an anoxic subregion; a relative hypoxia degree parameter is obtained by calculating the cerebral blood flow ratio of the hypoxia subregion to other regions of the tumor; historical treatment case data are deconstructed, and a dose-curative effect associated parameter set is established; training and outputting a dose adjustment strategy model for the hypoxia subregion; and generating a final radiotherapy dose planning scheme according to a dose adjustment value output by the model in combination with a clinical guide basic dose. Through a data-driven dose decision-making mechanism, the limitation of traditional uniform dose irradiation is overcome, so that an objective and reliable evaluation basis is provided for clinical selection and optimization of personalized treatment schemes.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Disclosed are methods of treating cancer comprising administering to a subject a treatment regimen comprising a compound of Formula (I): Formula (I), or a pharmaceutically acceptable salt thereof, and a PD-1 or PD-L1 antagonist.

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

Embodiments of the present invention include methods of targeting acidosis (low pH) within the tumor microenvironment (TME) through the use of cathodic electrochemical reactions (CER). Low pH is oncogenic by supporting immunosuppression. Electrochemical reactions create local pH effects when a current passes through an electrolytic substrate such as biological tissue. Electrolysis has been used with electroporation (destabilization of the lipid bilayer via an applied electric potential) to increase cell death areas. However, the regulated increase of pH through only the cathode electrode has been ignored as a possible method to alleviate TME acidosis, which could provide substantial immunotherapeutic benefits. Here, ex vivo modeling shows that CERs can intentionally elevate pH to an anti-tumor level and that increased alkalinity promotes activation of naïve macrophages. Embodiments of the invention include pairing CER treatment protocols with existing electric field-based cancer therapies or use as a stand-alone therapy.

The invention discloses a broad-spectrum combined medicine for treating liver cancer, which comprises purified water, tripterygium wilfordii alkaloid, tripterygium hypoglaucum alkaloid, chamaejasmine, gelsmium elegans alkaloid, xanthoxylin and various B medicines, and further comprises folic acid, vitamins, copper sulfate, zinc sulfate, manganese sulfate, yeast and penicillin sodium. Through the multi-component, multi-target and multi-path design, the medicine disclosed by the invention shows a potential effect of inhibiting the progress of liver cancer and good safety in cell experiments, animal models and human individual case observation. Cellular immunity and humoral immunity can be enhanced, the treatment cost is lower than that of a traditional treatment scheme, and no pain is caused during treatment.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

Described herein are gene features that provide prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, including immune checkpoint regulators such as Programmed Death Ligand 1 (PDL-1). Using the methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers indicate disease pathogenesis, which provides opportunities for selection of treatments, including treatment regimens intended to overcome tolerance mechanisms.

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3Kδ pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea / colitis, respiratory infections, and hematologic toxicities.

The invention relates to the technical field of medicines, and discloses an application of combination of bufalin and heme in preparation of a cancer treatment medicine. According to the invention, by means of an active metabonomics means, a key active metabolite-heme is locked through exogenous library screening and endogenous analysis, and the drug effect of bufalin is regulated by means of the active metabolite. Through verification, it is found that heme can cooperate with the synergistic drug effect in various cancer cell lines, and a new technical normal form based on an active metabolome for improving the drug effect of bufalin is provided. The pharmaceutical composition can improve the apoptosis induction ability of bufalin to different cancer cells, and provides powerful guiding significance for developing a novel treatment scheme in clinical medicine.

The invention belongs to the technical field of skin disease treatment and medicine, and particularly relates to an external pharmaceutical composition for treating atopic dermatitis and a preparation method and application thereof. The medicine composition is liquid medicine composed of blumea balsamifera oil, perfoliote knotweed herb and piper cubeba extract and is specially used for treating the atopic dermatitis (AD). According to the composition, the blumea balsamifera oil is innovatively used as a main component and cooperates with the perfoliote knotweed herb and the piper cubeba extract to form an efficient treatment scheme, and the curative effect of the composition is remarkably superior to that of a traditional method for singly using the blumea balsamifera oil. Experiments prove that the composition can effectively improve the skin barrier function, regulate immune disorder, reduce the levels of serum IgE and TSLP and inflammatory factors IL-4 and IFN-gamma, and reduce inflammatory cell infiltration, so that the AD symptom is relieved, and the recurrence rate is reduced.

Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.

The application discloses a medical expense insurance simulation decision method and system based on data fusion, and relates to the technical field of medical expense insurance simulation decision. When a target patient has obtained a current stage treatment scheme, but the system cannot determine part of the medication sites to be determined as a unique medication direction according to existing diagnosis information and completed examination results, the candidate medication direction is reserved first, then the supplementary candidate is formed according to the medication category, stage continuation state and subsequent processing path, and the supplementary result of the previous stage corresponding to the same to-be-supplemented site is combined to perform an overlay determination, and only the unoverlaid part generates the supplementary result of this round; when subsequent new data arrives, only the affected unoverlaid part that satisfies the boundary condition and no longer establishes the original support relationship is executed for local reopening, so that the current stage input that can be called by insurance simulation decision is formed.

The invention relates to the technical field of intelligent medical treatment, and discloses a pancreatic cancer evolution simulation and dynamic intervention system based on multi-model driving, and the system comprises a multi-source data fusion module which is used for accessing and processing patient data, and forming a multi-dimensional feature set; the model fusion construction module is integrated with a model coupler and can construct a patient-specific integrated calculation model; the twinborn calibration generation module is used for generating pancreatic cancer digital twinborn matched with the initial state of the patient; and the evolution simulation and intervention module is used for running the pancreatic cancer digital twins, simulating the natural evolution trajectory of the tumor and carrying out quantitative simulation on the input virtual treatment scheme effect. According to the method, by constructing the patient-specific digital twins, normal form transformation from static diagnosis to dynamic prediction is achieved, and a quantitative evaluation basis can be provided for selection of clinical treatment schemes.

The invention relates to a pharmaceutical composition containing a nucleic acid construct and a medical application thereof. Specifically, the invention relates to lipid nanoparticles as shown in a formula I, which can realize efficient delivery of exogenous target genes, so that the exogenous target genes are efficiently and quickly expressed in vivo, have the advantages of no gene integration risk and easiness in industrial amplification, are more ideal therapeutic schemes than naked plasmids, and can be used as gene therapeutic drugs for various diseases.

The pharmaceutical composition according to the present invention is used at specific therapeutic regimen and dosage, and can be usefully used for the prevention or treatment of fibrosis.

The application discloses a vanadium-based nano drug capable of reversing cisplatin drug resistance through multiple targets and a preparation method thereof.The preparation method of the drug comprises the following steps: (1) preparation of mesoporous silica; (2) vanadium ion doping; (3) surface amino modification; (4) loading of a Pt(IV) prodrug; and (5) PDGF modification on the surface of the drug-loaded nanoparticles, thereby obtaining the vanadium-based nano drug.The vanadium-based nano drug prepared by the method has excellent performance, can reverse cisplatin drug resistance through multiple targets, and provides a new idea for constructing a lung cancer precision treatment scheme for reversing cisplatin drug resistance through multiple targets.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.

This specification discloses a method for administering dexmedetomidine or a pharmaceutically acceptable salt thereof to human subjects. The disclosed method is particularly suitable for the treatment of agitation associated with neurodegenerative diseases and / or neuropsychiatric disorders or disorders (e.g., Alzheimer's disease).

The invention discloses a clinical pharmacy monitoring management method and system, and relates to the technical field of clinical pharmacy, and the method comprises an information acquisition module, an information supplement module, a medicine safety management module, a medicine curative effect monitoring module, and a medicine treatment scheme evaluation and optimization module. The method has the advantages that prescription source intervention is added, a previous medication list, allergy history and doctor-seeing information of other hospitals are additionally recorded, medical staff and doctor-seeing doctors are informed of all information of the patient in an intervention and additional recording mode, and the information is supported by electric connection and verified by examination reports after hospital admission, so that the doctor-seeing efficiency is improved, and the doctor-seeing efficiency is improved. All information is compared before diagnosis and medicine taking, follow-up work of medical staff is facilitated, the medicine taking direction of a doctor is confirmed, and the hospitalization treatment time of a patient is effectively shortened.

The invention discloses engineering mitochondria enriched with alpha2delta2 protein, the expression level of the alpha2delta2 protein in the mitochondria is higher than that of natural mitochondria, the expression quantity of the alpha2delta2 protein is 15-40 times that of the natural mitochondria, and the alpha2delta2 protein is enriched in the outer membrane of the mitochondria. The invention also discloses a preparation method of the engineered mitochondria enriched with the alpha2delta2 protein. The invention also discloses an application of the engineered mitochondria enriched with the alpha2delta2 protein in preparation of medicines for preventing and / or treating fibrosis diseases. In-vitro experiments prove that the engineered mitochondria can significantly enhance the ability of inhibiting fibroblast activation and collagen secretion, and the effect of the engineered mitochondria is far better than that of common mitochondria. The invention provides a brand-new and effective organelle level treatment scheme for solving the clinical problem of fibrosis.

The invention relates to a multifunctional music therapeutic apparatus which comprises a main treatment module provided with a music treatment module, and the main treatment module further comprises a multi-mode physical treatment module, a physiological parameter monitoring module, an interaction and display module and a power supply and safety protection module. The system further comprises an auxiliary operation module, and the auxiliary operation module comprises a therapeutic scheme management unit, a self-adaptive adjustment unit, a data recording and analyzing unit and a safety early warning unit. The multi-mode physical therapy module comprises an acousto-optic stimulation unit, a low-frequency pulse unit and a vibration massage unit; the physiological parameter monitoring module comprises a heart rate / blood oxygen monitoring unit adopting the PPG technology and a forehead single-lead electroencephalogram monitoring unit, and the forehead single-lead electroencephalogram monitoring unit is used for collecting alpha wave and beta wave signals; the self-adaptive adjusting unit receives data of the physiological parameter monitoring module in real time. The multifunctional music therapeutic apparatus integrates multiple therapeutic functions, and the curative effect brought by music therapy can be greatly improved.

Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.